[Distinguished Pioneer Lecture] From Aromatase Biology to Single-Cell/Spatial Transcriptomics Analysis: A Lifetime's Journey in Precision Oncology of Breast Cancer.
Shiuan Chen
King-Jen Chang
09:00 - 09:30
Session (1) From Evidence to Consensus: The Evolution and Global Impact of the NCCN Breast Cancer Guidelines: A Perspective from the Founding Chair of the NCCN Guidelines Panel for Breast Cancer
William John Gradishar
Ming-Feng Hou
09:30 - 10:00
Session (1) From Global to Local: Ethnic and Geographic Impact in the Treatment of Breast Cancer Patient
Shigehira Saji
Jyh-Cherng Yu
wendy wang
10:00 - 10:40
Session (1) Translating ctDNA Dynamics into Clinical Strategy: Innovation of Next-Generation SERD in 1L HR+/HER2- mBC
François-Clément Bidard
Ling-Ming Tseng
10:40 - 10:45
Group Photo
10:45 - 11:00
Coffee Break
11:00 - 11:40
Session (1) The Sustainable Efficacy of CDK4/6 Inhibitor Therapy in HR+/HER2- Node+ High-Risk Early Breast Cancer
Marc Thill
Ta-Chung Chao
11:40 - 12:10
Session (1) Impact and Pitfall of International Guideline and Real World Practice
François-Clément Bidard
William John Gradishar
Shigehira Saji
Marc Thill
Chiun-Sheng Huang
Yen-Shen Lu
Fang-Ming Chen
12:10 - 12:55
[Luncheon Symposium (1)] Treatment Landscape for HR+/HER2- mBC with PIK3CA Pathway Mutations
Erica L. Mayer
Yen-Shen Lu
12:55 - 13:10
Coffee Break
13:10 - 13:50
Session (2) Redefining the Therapeutic Role of TKIs in HER2-Positive Metastatic Breast Cancer
Virginia Borges
Fiona Tsui-Fen Cheng
13:50 - 14:30
Session (2) Redefining First-Line Treatment in HER2+ mBC: Insights from DESTINY-Breast09
Tom Wei-Wu Chen
Shin-Cheh Chen
14:30 - 15:10
Session (2) Defining the Optimal Sequence in HER2+ MBC: Balancing Category 1 Evidence with Emerging Frontline Data
Chi-Feng Chung
Ming-Shen Dai
15:10 - 15:30
Coffee Break
15:30 - 16:10
Session (2) Longer Survival and Better Quality of Life: Two Endpoints to Be Considered in Metastatic HER2-Positive MBC
Joohyuk Sohn
Ching-Hung Lin
16:10 - 16:50
Session (2) Improving Outcomes: Redefining High Risk and Care in HR+/HER2- Early Breast Cancer
Dejan Juric
Hsien-Tang Yeh
16:50 - 17:20
Session (2) From Immune Infiltration to Immune Intervention: The Changing Landscape of Breast Cancer Immunotherapy
Sherene Loi
Shyr-Ming Sheen-Chen
17:20 - 18:00
Session (2) Addressing Unmet Needs in TNBC: The Evolving Role of ADC Therapies
Ching-Hung Lin
Tsu-Yi Chao
Time (UTC+8)
Topic
Speaker
Moderator
Abstract
Slides
Video
09:30 - 09:50
[TBCS-GBCC-JBCS-SSO] Joint Session: De-escalation of Breast Surgery: Who Can Safely Receive Less?
Chin-Sheng Hung
Junwon Min
Kuo-Ting Lee
09:50 - 10:10
[TBCS-GBCC-JBCS-SSO] Joint Session: Can Axillary Surgery Be Safely Omitted After Neoadjuvant Therapy?
Laura S. Dominici
Junwon Min
Kuo-Ting Lee
10:10 - 10:30
[TBCS-GBCC-JBCS-SSO] Joint Session: Breast Surgery in Young and High-Risk Patients: Where Is the Limit of De-escalation?
Han-Byoel Lee
Junwon Min
Kuo-Ting Lee
10:30 - 10:50
[TBCS-GBCC-JBCS-SSO] Joint Session: Is There Still a Role for Surgery in De Novo Stage IV Breast Cancer?
Sung Gwe Ahn
Yutaka Yamamoto
Ming-Yang Wang
10:50 - 11:10
[TBCS-GBCC-JBCS-SSO] Joint Session: Precision Breast Surgery in Japan: Toward Surgical De-escalation After Systemic Therapy
Hideo Shigematsu
Yutaka Yamamoto
Ming-Yang Wang
11:10 - 11:30
[TBCS-GBCC-JBCS-SSO] Joint Session: Setting the Future Standard of Breast Surgery: The SSO Perspective
Mediget Teshome
Yutaka Yamamoto
Ming-Yang Wang
11:30 - 12:00
[TBCS-GBCC-JBCS-SSO] Joint Session: Discussion
Sung Gwe Ahn
Laura S. Dominici
Han-Byoel Lee
Junwon Min
Hideo Shigematsu
Mediget Teshome
Yutaka Yamamoto
Chin-Sheng Hung
Kuo-Ting Lee
Ming-Yang Wang
12:00 - 12:40
[Lunchron Symposium] Treatment Landscape Shift in 2L+ HR+/HER2− mBC: ESR1 Mutation and Oral SERD
Jason Aboudi Mouabbi
Jiun-I Lai
14:00 - 14:05
[Young Doctors Forum] Opening
Chi-Cheng Huang
14:05 - 14:30
[Young Doctors Forum] From Trials to Practice: Interpreting Global Evidence in Modern Breast Cancer Care
Marc Thill
14:30 - 14:55
[Young Doctors Forum] Beyond the Guidelines: Clinical Decision-Making in Modern Axillary Management
Laura S. Dominici
14:55 - 15:00
[Young Doctors Forum] Q&A
Laura S. Dominici
Marc Thill
15:00 - 15:05
Break
15:05 - 15:45
[Young Doctors Debate] “No Scar, No Axilla?” Can Axillary Surgery Be Completely Omitted in Initially cN0 HER2-Positive Breast Cancer Patients Achieving Radiologic and Pathological Complete Response in the Breast After Neoadjuvant Systemic Therapy?
Dewangga Ario
Dahn Byun
Chia-Hui Chu
Yuri Fujimoto
Kristalyn K. Gallagher
Chih-Hao Huang
Hsiang-Wei Huang
Chieh-Ni Kao
Mustafa Khanbhai
Hyung Suk Kim
Kwan Ho Lee
Pei-Hsuan Lee
Young-Won Lee
Nguyen Duc Toan
Chayanee Sae-Lim
Andrew Seto
Basilie Teoh
Nicola Raphaela Tison
I-Chen Tsai
Che-Cheng Yu
Chiao Lo
15:45 - 16:25
[Young Doctors Debate] Pull the Trigger or Stay the Course? Should Endocrine Therapy Be Preemptively Switched Based Solely on Plasma ESR1 Mutation Detection via ctDNA Before Radiologic Progression in HR+/HER2- Advanced Breast Cancer?
Desak Gede Agung Pramesti Devi
Saori Hayashi
Shih-Yu Huang
Chia-Yen Hung
Kibeom Kim
Mai Kitazawa
Takako Kuroda
Chi Hoon Lee
Jun-Hee Lee
Wen-Ying Lin
Wei-Nung Liu
Sangjoon Park
Arga Patrianagara
Shang-Hsuan Peng
Meng-Xia Su
Tomoe Taji
Jacqueline Tsai
Asdi Wihandono
Chan-Keng Yang
Jwo-Huey Yu
Tom Wei-Wu Chen
16:25 - 16:30
[Young Doctors Debate] Q&A Closing
Jeong Eon Lee
16:30 - 16:50
YDF/YDD Group Photo
17:10 - 17:50
The World's First NGS-Based Prognostic Assay and Real-World Clinical Experience in Korea
Wonshik Han
Chiun-Sheng Huang
Time (UTC+8)
Topic
Speaker
Moderator
Abstract
Slides
Video
10:30 - 16:00
Oral Presentation
16:30 - 17:05
[Nursing Care] Beyond Physical Recovery: Body Image, Dyadic Interaction, and Intimacy in Breast Cancer Survivorship Care
Su-Ying, Fang
Hsiu-Ling Chou
17:05 - 17:40
[Nursing Care] Beyond the Body: Reclaiming Who I Am -Psychological Healing and Readiness for Intimacy After Breast Cancer
[Breakfast Symposium] Beyond the Fatigue Score: Immune Cell Profiling, Cytokine Signatures, and Inflammatory Correlates of PG2 in Breast Cancer
Chun-Yu Liu
Ming-Han Yang
Kun-Ming Rau
08:50 - 09:20
Session (3) AI in BC Care: Translating AI into Precision Medicine
Serene Goh
Chi-Cheng Huang
09:20 - 09:50
Session (3) Surgical De-escalation After Neoadjuvant Therapy: When Less Is More
Susan Boolbol
Chen-Hsiang Chang
09:50 - 10:10
Coffee Break
10:10 - 10:40
Session (3) Cryoablation for Breast Cancer: 2026 Update
Michael Berry
Yao-Jen Chang
10:40 - 11:10
Session (3) Robotic Nipple-Sparing Mastectomy: Technique, Outcomes, and Future Directions
Antonio Toesca
Guo-Shiou Liao
11:10 - 11:30
Session (3) Discussion
Michael Berry
Susan Boolbol
Serene Goh
Antonio Toesca
Chi-Cheng Huang
Chen-Hsiang Chang
Yao-Jen Chang
Guo-Shiou Liao
11:30 - 12:10
Session (4) Advancing the Management of ER+ HER2- mBC: Integrating Evidence and Experience
Adam Matthew Brufsky
Liang-Chih Liu
12:10 - 12:55
[Luncheon Symposium (2)] One Step Further: Tackling the Unmet Needs to Reduce Recurrence Risk in HER2+ Breast Cancer
Chin-Yao Lin
Dar-Ren Chen
12:55 - 13:10
Coffee Break
13:10 - 13:50
Session (5) Emerging ADC Treatment Strategies in Metastatic HR+/HER2− Breast Cancer
Min Hwan Kim
Hsien-Kun Chang
13:50 - 14:30
Session (5) Evolving Treatment Landscape in HER2-Positive Early Breast Cancer (eBC): The Integration of ADC Therapies
Sibylle Loibl
Chiun-Sheng Huang
14:30 - 14:45
Coffee Break
14:45 - 15:25
Session (5)Solo or Duet - Elevating Outcomes for Patients Starting 1L mTNBC Therapy by Anti-Trop2 ADC
Dwan Ying Chang
Shou-Tung Chen
15:25 - 15:45
Session (5) Clinical experience with S-1 in Japan: evidence and practical integration in early breast cancer
Masahiro Takada
Yuan-Ching Chang
15:45 - 16:05
Session (5) Practical Insights on Using TS-1 as Adjuvant Therapy in HR+/HER2− Early Breast Cancer: Cases, Tolerability, and Results
Li-Kun Ko
Yuan-Ching Chang
16:05 - 16:35
Session (5) Disease Progression Under ADC, What Would We Do? Now and Future
Naoto T. Ueno
Wen-Hung Kuo
16:35 - 16:45
Award Ceremony
Yen-Shen Lu
Fang-Ming Chen
16:45 - 17:00
Closing
Yen-Shen Lu
Fang-Ming Chen
Time (UTC+8)
Topic
Speaker
Moderator
Abstract
Slides
Video
10:10 - 10:50
[Mini-Symposium] Evolving paradigms in HR+/HER2- eBC: The rise of next-generation oSERD
Hsu-Huan Chou
Wen-Ling Kuo
10:50 - 11:30
[Mini-Symposium] Real World Experience of Eribulin for Metastatic Breast Cancer
Cheng-Wei Chou
Shih-Che Shen
11:30 - 12:10
[Mini-Symposium] Effectiveness of CDK4/6 inhibitor treatment for HR+/HER2- metastatic breast cancer
Marc Thill
Chao-Ming Hung
12:10 - 12:50
[Luncheon Symposium (3)] From Access to Better Outcomes-The New Era of Early HER2-Positive Breast Cancer Care in Taiwan
Chih-Hao Huang
Hsien-Tang Yeh
12:50 - 13:00
[Robotic Surgery Special Session]Opening-Global Approval Status of da Vinci Robotics in Breast Surgery
Michael Berry
13:00 - 13:25
[Robotic Surgery Special Session] Pioneering Robotic Mastectomy with Insightful Perspectives
Antonio Toesca
Michael Berry
13:25 - 13:50
[Robotic Surgery Special Session] Learning Pathways and Training Models of Robotic Surgery
Tristen Park
Han-Byoel Lee
13:50 - 14:15
[Robotic Surgery Special Session] Elements that Constitute Successful Robotic Breast Surgical Practice
Wen-Ling Kuo
Ling-Ming Tseng
14:15 - 14:40
[Robotic Surgery Special Session] Reconstruction after Robotic Mastectomy
Alice Yao
Fiona Tsui-Fen Cheng
14:40 - 15:00
[Robotic Surgery Special Session] Panel Discussion
Michael Berry
Han-Byoel Lee
Tristen Park
Antonio Toesca
Alice Yao
Ling-Ming Tseng
Fiona Tsui-Fen Cheng
Wen-Ling Kuo
15:10 - 15:50
[Functional Recovery and Physical Therapy After Breast Cancer Surgery] From Surgical Success to Functional Recovery: Evidence-Based Physical Therapy in Comprehensive Breast Cancer Care and a Clinical Case
Yi Cheng Lin
Wendy TJ Wang
Ming-Feng Hou
Speech
Time
Topic
Role
Room
Biography
Education / Training
Professional and Research Experience
Awards & Honors
Selected Publications
topic
name
summary
You don't have permission to access this resource. Please contact the secretariat via tibcs@tibcs.org.tw if theres is any question. Thank you.